Buy now (tactical): price is sitting just above the key pivot/support area (~7.83) with momentum improving (MACD turning up) and sentiment supported by a newly announced $75M buyback.
Options positioning is bullish (puts relatively low vs calls), aligning with a near-term upside bias.
Key near-term levels: holding above 7.83 favors a push toward 8.36 then 8.68.
Profitability: Net income $108.6M, -4009% YoY and EPS 1.26, -2620% YoY → large YoY decline suggests prior-period comparables/one-time items; earnings trend is not clean despite high absolute net income.
Gross margin: 89.26% (down ~5.05% YoY) → still very high, but slightly compressing.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Ratings posture: still broadly constructive (Buy/Outperform maintained), but expectations have been materially reset.
Price target trend (recent):
2026-01-23 H.C. Wainwright Buy, PT $13 (cut from $18)
2026-01-21 RBC Outperform, PT $13 (cut from $22)
2026-01-08 Truist Buy, PT $16 (cut from $20)
2025-11-13 H.C. Wainwright Buy, PT $18 (raised from $17 at the time)
Wall Street pros: buyback + high margins + continued bullish ratings.
Wall Street cons: DefenCath guidance disappointment and increased emphasis on execution/clinical milestones.
Politicians/congress: No recent congress trading data available; no politician activity provided in the dataset.
Wall Street analysts forecast CRMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRMD is 17 USD with a low forecast of 14 USD and a high forecast of 22 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast CRMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRMD is 17 USD with a low forecast of 14 USD and a high forecast of 22 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.350
Low
14
Averages
17
High
22
Current: 7.350
Low
14
Averages
17
High
22
H.C. Wainwright
Buy
downgrade
$18 -> $13
AI Analysis
2026-01-23
Reason
H.C. Wainwright
Price Target
$18 -> $13
AI Analysis
2026-01-23
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on CorMedix to $13 from $18 and keeps a Buy rating on the shares. The firm says expectations have been reset following the updated 2026-2027 DefenCath guidance. CorMedix has entered the next phase of the story where clinical execution now matters more than commercial execution, the analyst tells investors in a research note.
RBC Capital
Outperform -> NULL
downgrade
$22 -> $13
2026-01-21
Reason
RBC Capital
Price Target
$22 -> $13
2026-01-21
downgrade
Outperform -> NULL
Reason
RBC Capital lowered the firm's price target on CorMedix to $13 from $22 and keeps an Outperform rating on the shares. The firm updated models for several biotech companies after meeting with managements.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CRMD
